153 related articles for article (PubMed ID: 8294896)
1. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
[TBL] [Abstract][Full Text] [Related]
2. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
3. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72.974A in normal volunteers.
Hinze C; Harland D; Zreika M; Dulery B; Hardenberg J
J Neural Transm Suppl; 1990; 32():203-9. PubMed ID: 2089092
[TBL] [Abstract][Full Text] [Related]
5. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
Myllylä VV; Sotaniemi KA; Aasly J; Sjaastad O; Rinne U; McIntyre T; Cremer G
Adv Neurol; 1993; 60():676-80. PubMed ID: 8420209
[No Abstract] [Full Text] [Related]
6. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
Zreika M; Fozard JR; Dudley MW; Bey P; McDonald IA; Palfreyman MG
J Neural Transm Park Dis Dement Sect; 1989; 1(4):243-54. PubMed ID: 2597310
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Bainbridge JL; Page RL; Ruscin JM
Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man.
Dulery BD; Schoun J; Zreika M; Dow J; Huebert N; Hinze C; Haegele KD
Arzneimittelforschung; 1993 Mar; 43(3):297-302. PubMed ID: 8489556
[TBL] [Abstract][Full Text] [Related]
10. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Chen JJ; Wilkinson JR
J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
13. Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.
Palfreyman MG; McDonald IA; Bey P; Danzin C; Zreika M; Cremer G
J Neural Transm Suppl; 1994; 41():407-14. PubMed ID: 7931257
[TBL] [Abstract][Full Text] [Related]
14. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Youdim MB; Gross A; Finberg JP
Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial.
Stoltz M; Reynolds D; Elkins L; Salazar D; Weir S
Clin Pharmacol Ther; 1995 Sep; 58(3):342-53. PubMed ID: 7554709
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
18. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
Dow J; Piriou F; Wolf E; Dulery BD; Haegele KD
Drug Metab Dispos; 1994; 22(5):738-49. PubMed ID: 7835226
[TBL] [Abstract][Full Text] [Related]
19. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species.
Yu PH; Zuo DM
Biochem Pharmacol; 1992 Jan; 43(2):307-12. PubMed ID: 1739419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
